The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global amyotrophic lateral sclerosis treatment market size reached US$ 681.7 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 962.08 Million by 2027, exhibiting a growth rate (CAGR) of 5.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Amyotrophic Lateral Sclerosis Treatment (ALS) refers to a degenerative disease that affects the nerve cells in the spinal cord and brain, resulting in loss of muscle control. It primarily occurs due to gene mutation, disorganized immune response, chemical imbalance, etc. Some of the common symptoms of ALS include muscle stiffness, twitching of the muscles, weakness in the legs or arms, cognitive and behavioral changes, trouble in swallowing, slurred speech, etc. The diagnosis of ALS relies on medical history, physical examination, electrodiagnostic testing, and neuroimaging.
The rising incidences of neurodegenerative disorders due to changing lifestyle patterns and hectic schedules of the individuals are primarily driving the Amyotrophic Lateral Sclerosis Treatment treatment market. Besides this, the expanding geriatric population, who are more susceptible to such neurological ailments, is also augmenting the market growth. Furthermore, several NGOs and private organizations are undertaking numerous initiatives to increase awareness regarding the diagnosis and treatment of ALS among the masses. This, in turn, is creating a positive outlook for the market. Additionally, the growing penetration of targeted and symptomatic treatment options for ALS is acting as a significant growth-inducing factor. Moreover, the elevating focus on clinical trials and faster approval of oral drugs for ALS treatment is also bolstering the market growth. Moreover, the increasing strategic collaborations among various research institutes to develop innovative treatment procedures that aim at enhancing muscle function, immune modulation, and neuroprotection are further catalyzing the global market. In the coming years, the continuous upgradation of healthcare infrastructures along with elevating penetration of refurbishment policies will continue to drive the global Amyotrophic Lateral Sclerosis Treatment (ALS) market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global amyotrophic lateral sclerosis treatment market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on treatment and distribution channel.
Breakup by Treatment:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AB Science, Ascend Pharmaceuticals LLC, BrainStorm Cell Therapeutics Inc., Corestem Inc., Cytokinetics Inc., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ITF Pharma (Italfarmaco S.p.A), Mitsubishi Chemical Group Corpotion, Revalesio Corporation and Treeway B.V.
|Base Year of the Analysis||2021|
|Segment Coverage||Treatment, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AB Science, Ascend Pharmaceuticals LLC, BrainStorm Cell Therapeutics Inc., Corestem Inc., Cytokinetics Inc., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ITF Pharma (Italfarmaco S.p.A), Mitsubishi Chemical Group Corpotion, Revalesio Corporation and Treeway B.V.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at